Annual CFF
$185.75 M
+$55.42 M+42.53%
December 31, 2024
Summary
- As of March 7, 2025, NTLA annual cash flow from financing activities is $185.75 million, with the most recent change of +$55.42 million (+42.53%) on December 31, 2024.
- During the last 3 years, NTLA annual CFF has fallen by -$550.94 million (-74.79%).
- NTLA annual CFF is now -74.79% below its all-time high of $736.69 million, reached on December 31, 2021.
Performance
NTLA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$2.32 M
-$79.88 M-97.18%
December 31, 2024
Summary
- As of March 7, 2025, NTLA quarterly cash flow from financing activities is $2.32 million, with the most recent change of -$79.88 million (-97.18%) on December 31, 2024.
- Over the past year, NTLA quarterly CFF has dropped by -$57.67 million (-96.14%).
- NTLA quarterly CFF is now -99.65% below its all-time high of $668.68 million, reached on September 30, 2021.
Performance
NTLA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$185.75 M
-$104.17 M-35.93%
December 31, 2024
Summary
- As of March 7, 2025, NTLA TTM cash flow from financing activities is $185.75 million, with the most recent change of -$104.17 million (-35.93%) on December 31, 2024.
- Over the past year, NTLA TTM CFF has dropped by -$2.35 million (-1.25%).
- NTLA TTM CFF is now -80.82% below its all-time high of $968.50 million, reached on September 30, 2021.
Performance
NTLA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
NTLA Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +42.5% | -96.1% | -1.3% |
| 3 y3 years | -74.8% | +1.6% | -74.8% |
| 5 y5 years | +143.0% | -88.2% | +143.0% |
NTLA Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -74.8% | +42.5% | -99.5% | +4.3% | -74.8% | +133.7% |
| 5 y | 5-year | -74.8% | +143.0% | -99.7% | +288.1% | -80.8% | +143.0% |
| alltime | all time | -74.8% | +361.9% | -99.7% | +225.0% | -80.8% | >+9999.0% |
Intellia Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $185.75 M(+42.5%) | $2.32 M(-97.2%) | $185.75 M(-35.9%) |
| Sep 2024 | - | $82.19 M(+99.3%) | $289.91 M(+27.8%) |
| Jun 2024 | - | $41.25 M(-31.2%) | $226.82 M(+20.6%) |
| Mar 2024 | - | $59.99 M(-43.7%) | $188.09 M(+44.3%) |
| Dec 2023 | $130.32 M(-77.6%) | $106.48 M(+457.4%) | $130.32 M(-75.4%) |
| Sep 2023 | - | $19.10 M(+659.2%) | $529.60 M(-0.9%) |
| Jun 2023 | - | $2.52 M(+13.3%) | $534.48 M(-0.6%) |
| Mar 2023 | - | $2.22 M(-99.6%) | $537.86 M(-7.7%) |
| Dec 2022 | $582.96 M(-20.9%) | $505.76 M(+2009.4%) | $582.96 M(+633.5%) |
| Sep 2022 | - | $23.98 M(+306.7%) | $79.47 M(-89.0%) |
| Jun 2022 | - | $5.89 M(-87.5%) | $724.17 M(-0.2%) |
| Mar 2022 | - | $47.32 M(+1975.4%) | $725.41 M(-1.5%) |
| Dec 2021 | $736.69 M(+98.2%) | $2.28 M(-99.7%) | $736.69 M(-23.9%) |
| Sep 2021 | - | $668.68 M(+9274.5%) | $968.50 M(+222.4%) |
| Jun 2021 | - | $7.13 M(-87.8%) | $300.42 M(-29.4%) |
| Mar 2021 | - | $58.59 M(-75.0%) | $425.51 M(+14.5%) |
| Dec 2020 | $371.78 M(+386.4%) | $234.09 M(>+9900.0%) | $371.78 M(+136.4%) |
| Sep 2020 | - | $597.00 K(-99.5%) | $157.25 M(-22.6%) |
| Jun 2020 | - | $132.22 M(+2618.4%) | $203.05 M(+162.7%) |
| Mar 2020 | - | $4.86 M(-75.1%) | $77.30 M(+1.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | $76.43 M(+90.1%) | $19.56 M(-57.8%) | $76.43 M(-12.2%) |
| Sep 2019 | - | $46.40 M(+617.0%) | $87.03 M(+103.3%) |
| Jun 2019 | - | $6.47 M(+61.8%) | $42.81 M(+14.2%) |
| Mar 2019 | - | $4.00 M(-86.7%) | $37.50 M(-6.8%) |
| Dec 2018 | $40.22 M(-71.9%) | $30.16 M(+1283.6%) | $40.22 M(-73.6%) |
| Sep 2018 | - | $2.18 M(+88.7%) | $152.17 M(+1.2%) |
| Jun 2018 | - | $1.16 M(-82.8%) | $150.36 M(+0.5%) |
| Mar 2018 | - | $6.72 M(-95.3%) | $149.65 M(+4.7%) |
| Dec 2017 | $142.98 M(-14.5%) | $142.12 M(>+9900.0%) | $142.98 M(>+9900.0%) |
| Sep 2017 | - | $371.00 K(-16.8%) | $1.13 M(-202.3%) |
| Jun 2017 | - | $446.00 K(+848.9%) | -$1.10 M(-100.7%) |
| Mar 2017 | - | $47.00 K(-82.0%) | $168.55 M(+0.7%) |
| Dec 2016 | $167.30 M(+138.0%) | $261.00 K(-114.1%) | $167.30 M(+0.4%) |
| Sep 2016 | - | -$1.85 M(-101.1%) | $166.59 M(-29.2%) |
| Jun 2016 | - | $170.09 M(<-9900.0%) | $235.16 M(+263.1%) |
| Mar 2016 | - | -$1.20 M(+162.1%) | $64.77 M(-7.9%) |
| Dec 2015 | $70.29 M | -$456.00 K(-100.7%) | $70.29 M(-0.6%) |
| Sep 2015 | - | $66.72 M(<-9900.0%) | $70.74 M(+1656.3%) |
| Jun 2015 | - | -$300.00 K(-106.9%) | $4.03 M(-6.9%) |
| Mar 2015 | - | $4.33 M | $4.33 M |
FAQ
- What is Intellia Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Intellia Therapeutics?
- What is Intellia Therapeutics annual CFF year-on-year change?
- What is Intellia Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Intellia Therapeutics?
- What is Intellia Therapeutics quarterly CFF year-on-year change?
- What is Intellia Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Intellia Therapeutics?
- What is Intellia Therapeutics TTM CFF year-on-year change?
What is Intellia Therapeutics annual cash flow from financing activities?
The current annual CFF of NTLA is $185.75 M
What is the all time high annual CFF for Intellia Therapeutics?
Intellia Therapeutics all-time high annual cash flow from financing activities is $736.69 M
What is Intellia Therapeutics annual CFF year-on-year change?
Over the past year, NTLA annual cash flow from financing activities has changed by +$55.42 M (+42.53%)
What is Intellia Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of NTLA is $2.32 M
What is the all time high quarterly CFF for Intellia Therapeutics?
Intellia Therapeutics all-time high quarterly cash flow from financing activities is $668.68 M
What is Intellia Therapeutics quarterly CFF year-on-year change?
Over the past year, NTLA quarterly cash flow from financing activities has changed by -$57.67 M (-96.14%)
What is Intellia Therapeutics TTM cash flow from financing activities?
The current TTM CFF of NTLA is $185.75 M
What is the all time high TTM CFF for Intellia Therapeutics?
Intellia Therapeutics all-time high TTM cash flow from financing activities is $968.50 M
What is Intellia Therapeutics TTM CFF year-on-year change?
Over the past year, NTLA TTM cash flow from financing activities has changed by -$2.35 M (-1.25%)